Alterity Therapeutics (ASX:ATH) has secured $20 million in new funding to accelerate the development of its lead drug candidate ATH434, a potential disease-modifying therapy for multiple system atrophy (MSA), a rare and devastating neurodegenerative disorder. …
Alterity Therapeutics secures $20 million to advance neurodegenerative disease pipeline
September 8, 2025 Australian Biotech
Latest Video
New Stories
-
US childhood vaccine move away from combinations contrasts with Australia’s national schedule
August 12, 2026 - - Latest News -
A sage appointment that puts DBG Health another step closer to a serious understanding of decision-making
August 12, 2026 - - Latest News -
Former minister joins DBG Health board as company broadens healthcare ambition
August 12, 2026 - - Latest News -
How education exposes the moral and ethical limits of our health decision-making
August 11, 2026 - - Latest News -
Percheron turns to former Arovella chief Michael Baker for next phase of HMBD 002 development
August 10, 2026 - - Latest News -
Australian company points to encouraging survival signal in mesothelioma CAR-T study
August 10, 2026 - - Australian Biotech -
GBMA White Paper calls for reforms to strengthen supply chain resilience
August 10, 2026 - - Latest News